Literature DB >> 17365861

Platelet aggregation in obese and diabetic subjects: association with leptin level.

Chiyo Sugiyama1, Masayoshi Ishizawa, Kazuo Kajita, Hiroyuki Morita, Yoshihiro Uno, Kenji Matsubara, Masami Matsumoto, Takahide Ikeda, Tatsuo Ishizuka.   

Abstract

To clarify the relationship between serum leptin concentration and platelet aggregation mechanism, we investigated serum leptin concentration and agonist-induced platelet aggregation in eight obese subjects and eight non-obese and non-diabetic controls. In addition we also measured them in 15 type 2 diabetic subjects and 17 control subjects. Maximum platelets aggregation rate (MPAR) in control and diabetic subjects by adenosine diphosphate (ADP), collagen and thrombin were measured by aggregometer after pretreatment with 100 ng/ml leptin for 60 min. The MPAR by 0.15 U/ml thrombin stimulation in leptin-treated platelet in the controls was significantly increased compared with that in non-treated platelets, but not by ADP and collagen stimulation. Despite a significantly higher concentration of leptin in obese subjects, agonist-induced platelet aggregation in obese subjects was not different from that in controls. There were no significant differences in serum leptin concentration and MPAR by various agonists between diabetic and control subjects. When MPAR by ADP in the diabetic subjects was divided into two groups (high group: >50%, low group: <50%), the serum leptin concentration in the high group was significantly increased, compared with that in the low group. These results suggest that ADP-induced platelet aggregation may be associated with serum leptin concentration in diabetic subjects, and that leptin-associated platelet aggregation may affect the development of cardiovascular complications in obese and diabetic subjects.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17365861     DOI: 10.1080/09537100600819115

Source DB:  PubMed          Journal:  Platelets        ISSN: 0953-7104            Impact factor:   3.862


  5 in total

1.  Improved prediction of HIT in the SICU using an improved model of the Warkentin 4-T system: 3-T.

Authors:  Matthew B Bloom; Jeffrey Johnson; Oksana Volod; Ernest Y Lee; Terris White; Daniel R Margulies
Journal:  Am J Surg       Date:  2019-07-29       Impact factor: 2.565

Review 2.  Diabetes and antiplatelet therapy: from bench to bedside.

Authors:  Jose R Rivas Rios; Francesco Franchi; Fabiana Rollini; Dominick J Angiolillo
Journal:  Cardiovasc Diagn Ther       Date:  2018-10

Review 3.  Platelet function profiles in patients with diabetes mellitus.

Authors:  Fabiana Rollini; Francesco Franchi; Ana Muñiz-Lozano; Dominick J Angiolillo
Journal:  J Cardiovasc Transl Res       Date:  2013-02-13       Impact factor: 4.132

Review 4.  Endothelial dysfunction and platelet hyperactivity in type 2 diabetes mellitus: molecular insights and therapeutic strategies.

Authors:  Raminderjit Kaur; Manpreet Kaur; Jatinder Singh
Journal:  Cardiovasc Diabetol       Date:  2018-08-31       Impact factor: 9.951

5.  Leptin decreases the expression of low-density lipoprotein receptor via PCSK9 pathway: linking dyslipidemia with obesity.

Authors:  Ying Du; Sha Li; Chuan-Jue Cui; Yan Zhang; Sheng-Hua Yang; Jian-Jun Li
Journal:  J Transl Med       Date:  2016-09-23       Impact factor: 5.531

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.